1. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
- Author
-
Ella, Raches, Reddy, Siddarth, Blackwelder, William, Potdar, Varsha, Yadav, Pragya, Sarangi, Vamshi, Aileni, Vinay K, Kanungo, Suman, Rai, Sanjay, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar, Mohapatra, Satyajit, Pandey, Anil, Ranganadin, Pajanivel, Gumashta, Raghavendra, Multani, Manish, Mohammad, Shameem, Bhatt, Parul, Kumari, Laxmi, Sapkal, Gajanan, Gupta, Nivedita, Abraham, Priya, Panda, Samiran, Prasad, Sai, Bhargava, Balram, Ella, Krishna, Vadrevu, Krishna Mohan, Aggarwal, P., Aglawe, V., Ali, A., Anand, N., Awad, N., Bafna, V., Balasubramaniyam, G., Bandkar, A., Basha, P., Bharge, V., Bhate, A., Bhate, S., Bhavani, V., Bhosale, R., Chalapathy, DV, Chaubal, C., Chaudhary, D., Chavan, A., Desai, P., Dhodi, D., Dutta, S., Garg, R., Garg, K., George, M., Goyal, P., Guleria, R., Gupta, S., Jain, M., Jain, M.K., Jindal, S., Kalra, M., Kant, S., Khosla, P., Kulkarni, P., Kumar, P., Kumar, Y., Majumdar, A., Meshram, P., Mishra, V., Mohanty, S., Nair, J., Pandey, S., Panigrahi, S.K., Patil, B., Patil, V., Rahate, P., Raj, V., Ramanand, S., Rami, K., Ramraj, B., Rane, S., Rao, E.V., Rao, N., Raphael, R., Reddy, G., Redkar, V., Redkar, S., Sachdeva, A., Saha, J., Sahoo, J., Sampath, P., Savith, A., Shah, M., Shanmugam, L., Sharma, R., Sharma, P., Sharma, D., Singh, A., Singh, J., Singh, P., Sivaprakasam, S., Subramaniam, S., Sudheer, D., Tandon, S., Tariq, M., Tripathi, V., Vable, M., Verma, R., and Waghmare, S.
- Abstract
We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.
- Published
- 2021
- Full Text
- View/download PDF